Key result
Prior authorization was required for 72% of 283 pediatric pulmonary hypertension prescriptions, causing mean delays of 4.2 days despite a 97% ultimate approval rate.
Why the study?
To quantify the prior authorization burden for pediatric pulmonary hypertension medications at an accredited center.
Observational (n=53)
No
Prior authorizations for pediatric pulmonary hypertension medications create significant administrative burden and delays, despite a 97% ultimate approval rate.
PA requirements impose substantial administrative burden in pediatric PH despite high approval; leaves open whether policy reforms improve timely access.
This study quantified prior authorization (PA)-insurance-required approval-burden for pediatric pulmonary hypertension (PH) at an accredited center. Among 53 patients, 72% of 283 prescriptions between 2021 and 2023 required PA, with non-FDA-approved medications showing highest volume. Despite 97% approval and all patients ultimately obtaining medication, delays (mean 4.2 days), repeat requests (39%), and reliance on patient assistance programs created significant administrative burden. Results highlight the need for policy reform to ensure timely, equitable access to essential therapies.
No takes yet. Share an insight, caveat, or question.
Yung et al. (2025) conducted an observational in Pediatric pulmonary hypertension (n=53). Prior authorization (PA) requirements was evaluated on Proportion of prescriptions requiring prior authorization. Prior authorization was required for 72% of 283 pediatric pulmonary hypertension prescriptions, causing mean delays of 4.2 days despite a 97% ultimate approval rate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: